Martin Buckland

Martin Buckland has more than 30 years of commercial, corporate and business development experience in the pharmaceutical and biotechnology industries. He is currently Chief Corporate Officer of Astex Pharmaceuticals, Inc. and was responsible for negotiating many of the company's collaboration and licensing agreements, as well as the merger of Astex Therapeutics Limited with SuperGen, Inc. and the subsequent sale of the company to Otsuka Pharmaceutical. He joined Astex from Elan Pharmaceuticals, where he held the position of Vice President of Global Business Development. His prior experience includes a variety of business development and commercial management roles with Quintiles, Xenova and Celltech. He has a BA in Chemistry and a DPhil from the University of Oxford, UK, and an MBA from the Open Business School.